Get the Stockscreener App
4.94
13.56%
0.59
Pre-market:
4.99
0.05
+1.01%
Prime Medicine Inc stock is traded at $4.94, with a volume of 6.65M.
It is up +13.56% in the last 24 hours and down -10.83% over the past month.
Prime Medicine Inc is a biotechnology company committed to delivering genetic therapies to address diseases by deploying gene editing technology, Prime Editing. The Prime Editing technology is a next-generation technology that can search and replace to restore normal genetic function in the genome and can treat a wide spectrum of diseases with high unmet medical needs and efficient and broad gene editing technology.
See More
Previous Close:
$4.35
Open:
$4.37
24h Volume:
6.65M
Relative Volume:
1.74
Market Cap:
$664.80M
Revenue:
-
Net Income/Loss:
$-217.44M
P/E Ratio:
-2.2765
EPS:
-2.17
Net Cash Flow:
$-205.20M
1W Performance:
-7.32%
1M Performance:
-10.83%
6M Performance:
+185.55%
1Y Performance:
+27.32%
1-Day Range:
$4.31
$5.025
1-Week Range:
$4.31
$5.20
52-Week Range:
$1.11
$6.94
Prime Medicine Inc Stock (PRME) Company Profile
Name
Prime Medicine Inc
Sector
Industry
Phone
617-465-0013
Address
60 FIRST ST., CAMBRIDGE
Compare PRME with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
PRME
Prime Medicine Inc
|
4.94 | 775.49M | 0 | -217.44M | -205.20M | -2.17 |
|
VRTX
Vertex Pharmaceuticals Inc
|
425.57 | 107.66B | 11.39B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
651.80 | 68.74B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
456.04 | 58.93B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
818.50 | 50.51B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
189.60 | 41.29B | 447.02M | -1.18B | -868.57M | -6.1812 |
Prime Medicine Inc Stock (PRME) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| May-27-25 | Downgrade | Citigroup | Buy → Neutral |
| May-20-25 | Downgrade | H.C. Wainwright | Buy → Neutral |
| May-20-25 | Downgrade | JP Morgan | Overweight → Neutral |
| Dec-10-24 | Initiated | JMP Securities | Mkt Outperform |
| May-20-24 | Initiated | H.C. Wainwright | Buy |
| May-16-24 | Upgrade | Citigroup | Neutral → Buy |
| Apr-22-24 | Initiated | Chardan Capital Markets | Buy |
| Apr-08-24 | Initiated | TD Cowen | Buy |
| Apr-03-24 | Initiated | Wedbush | Outperform |
| Jan-16-24 | Downgrade | Stifel | Buy → Hold |
| Dec-08-23 | Initiated | Citigroup | Neutral |
| Oct-09-23 | Initiated | BMO Capital Markets | Outperform |
| Jul-31-23 | Initiated | Guggenheim | Buy |
| Apr-18-23 | Initiated | Stifel | Buy |
| Nov-14-22 | Initiated | Goldman | Neutral |
| Nov-14-22 | Initiated | JP Morgan | Overweight |
| Nov-14-22 | Initiated | Jefferies | Buy |
| Nov-14-22 | Initiated | Morgan Stanley | Equal-Weight |
View All
Prime Medicine Inc Stock (PRME) Latest News
Is Prime Medicine Inc. stock supported by strong fundamentalsJuly 2025 News Drivers & Smart Money Movement Alerts - newser.com
How Prime Medicine Inc. stock performs in weak economyJuly 2025 Spike Watch & Weekly Market Pulse Alerts - newser.com
Momentum divergence signals in Prime Medicine Inc. chartJuly 2025 PostEarnings & Precise Buy Zone Identification - newser.com
Price momentum metrics for Prime Medicine Inc. explained2025 Stock Rankings & Free AI Powered Buy and Sell Recommendations - newser.com
Prime Medicine’s Price Target Revision Sparks Market Interest - StocksToTrade
Prime Medicine Eyes Expansion with Strategic Partnerships and Investor Engagement - timothysykes.com
Prime Medicine, Inc. (NYSE:PRME) Receives Average Rating of "Moderate Buy" from Analysts - MarketBeat
Prime Medicine’s Investor Activities and Upcoming Developments Boost Market Interest - StocksToTrade
Prime Medicine Stock Poised for Strategic Growth With New Developments - timothysykes.com
Will Prime Medicine Inc. stock outperform growth indexesWeekly Investment Report & Fast Entry Momentum Alerts - newser.com
Prime Medicine (NASDAQ:PRME) Shares Up 9.9%Time to Buy? - MarketBeat
Prime Medicine (NYSE:PRME) Trading 11.9% HigherWhat's Next? - MarketBeat
Sumitomo Mitsui Trust Group Inc. Has $3.94 Million Position in Prime Medicine, Inc. $PRME - MarketBeat
How institutional ownership impacts Prime Medicine Inc. stock2025 Big Picture & Safe Capital Growth Tips - newser.com
PRME Stock Surge: A Buying Opportunity? - StocksToTrade
Institutional investors in Prime Medicine, Inc. (NASDAQ:PRME) see US$174m decrease in market cap last week, although long-term gains have benefitted them. - Yahoo Finance
Does Prime Medicine Inc. qualify in momentum factor screeningEarnings Beat & Weekly High Potential Stock Alerts - newser.com
Technical signs of recovery in Prime Medicine Inc.Market Trend Review & Weekly Hot Stock Watchlists - newser.com
Combining price and volume data for Prime Medicine Inc.Portfolio Value Summary & Weekly Chart Analysis and Trade Guides - newser.com
Using economic indicators to assess Prime Medicine Inc. potentialWeekly Profit Report & AI Based Buy and Sell Signals - newser.com
How Prime Medicine Inc. stock reacts to job market dataJuly 2025 Summary & High Conviction Buy Zone Alerts - newser.com
IQ EQ FUND MANAGEMENT IRELAND Ltd Reduces Stock Holdings in Prime Medicine, Inc. $PRME - MarketBeat
Published on: 2025-10-31 03:29:26 - newser.com
Smart tools for monitoring Prime Medicine Inc.’s price actionJuly 2025 Snapshot & AI Forecasted Stock Moves - newser.com
Why Prime Medicine Inc. stock appeals to analystsWeekly Trade Recap & Intraday High Probability Alerts - newser.com
Comparing Prime Medicine Inc. in custom built stock radarsMarket Performance Recap & Stock Portfolio Risk Management - newser.com
Can Prime Medicine Inc. stock outperform in 2025 bull marketTrend Reversal & Daily Technical Forecast Reports - newser.com
Prime Medicine to Host Virtual KOL Event to Showcase Wilson’s Disease Strategy - The Manila Times
News impact scoring models applied to Prime Medicine Inc.Weekly Trade Review & Real-Time Volume Analysis - newser.com
Prime Medicine Update Reveals Latest Trends in Healthcare Stocks - Kalkine Media
Prime Medicine (NASDAQ:PRME) Trading Down 5.8%Here's Why - MarketBeat
Prime Medicine (NYSE:PRME) Stock Price Down 6.5%Here's Why - MarketBeat
Prime Medicine (NYSE:PRME) Shares Gap DownShould You Sell? - MarketBeat
Prime Medicine (NASDAQ:PRME) Shares Gap DownHere's What Happened - MarketBeat
Published on: 2025-10-28 06:42:01 - newser.com
Prime Medicine Inc Stock (PRME) Financials Data
Revenue
Net Income
Cash Flow
EPS
Prime Medicine Inc Stock (PRME) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| NELSEN ROBERT | Director |
Aug 01 '25 |
Buy |
3.30 |
3,030,300 |
9,999,990 |
6,230,300 |
| ARCH Venture Partners XII, LLC | 10% Owner |
Aug 01 '25 |
Buy |
3.30 |
3,030,300 |
9,999,990 |
6,230,300 |
| ARCH Venture Partners X, LLC | 10% Owner |
Aug 01 '25 |
Buy |
3.30 |
3,030,300 |
9,999,990 |
6,230,300 |
| Liu David R. | 10% Owner |
Jun 30 '25 |
Buy |
2.52 |
21,000 |
52,830 |
20,240,945 |
| Liu David R. | 10% Owner |
Jun 23 '25 |
Buy |
2.16 |
21,000 |
45,402 |
20,219,945 |
| Liu David R. | 10% Owner |
Jun 16 '25 |
Buy |
1.49 |
21,000 |
31,196 |
20,198,945 |
| Liu David R. | 10% Owner |
Jun 11 '25 |
Buy |
1.60 |
21,000 |
33,590 |
20,177,945 |
| Brudnick Richard | Chief Business Officer |
May 20 '25 |
Buy |
1.19 |
20,000 |
23,790 |
20,000 |
| LEE ANN L. | Chief Technical Officer |
May 21 '25 |
Buy |
1.13 |
100,000 |
113,000 |
100,000 |
| Reine Allan | Chief Executive Officer |
May 21 '25 |
Buy |
1.18 |
125,000 |
147,150 |
125,000 |
1.62%
0.21%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):